Title :

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Author(s) :

Guièze, Romain [Auteur]
CHU Estaing [Clermont-Ferrand]
Eikema, Diderik-Jan [Auteur]
Koster, Linda [Auteur]
Schetelig, Johannes [Auteur]
Sengeloev, Henrik [Auteur]
Passweg, Jakob [Auteur]
Finke, Jürgen [Auteur]
Arat, Mutlu [Auteur]
Broers, Annoek E. C. [Auteur]
Stölzel, Friedrich [Auteur]
Byrne, Jenny [Auteur]
Castilla-Llorente, Cristina [Auteur]
Institut Gustave Roussy [IGR]
Dreger, Peter [Auteur]
Eder, Matthias [Auteur]
Gedde-Dahl, Tobias [Auteur]
Kröger, Nicolaus [Auteur]
Ribera Santasusana, Josep Maria [Auteur]
Richardson, Deborah [Auteur]
Rambaldi, Alessandro [Auteur]
Yañez, Lucrecia [Auteur]
Van Gelder, Michel [Auteur]
Drozd-Sokolowska, Joanna [Auteur]
Raj, Kavita [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Tournilhac, Olivier [Auteur]
CHU Estaing [Clermont-Ferrand]
Mclornan, Donal P. [Auteur]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

59

Pages :

950–956

Publication date :

2024-07

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the ...
Show more >Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3–63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9–11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells. Eighteen (27.3%) patients had a matched sibling donor, 24 (36.4%) a matched unrelated donor and the remaining were mismatched. Median follow-up was 6.6 years; 1- and 3- year overall and progression free survival (PFS) (95% CI) was 65% (54–77) and 39% (27–51) and 53% (41–65) and 29% (18–40), respectively. Patients in CR at time of allo-HCT had significantly better 3-year PFS (39% vs. 21%, p = 0.032). Cumulative incidences of grade II–IV acute graft versus host disease (GVHD) at day +100 was 41% (95% CI 29–53) and chronic GVHD at 3 years was 53% (95% CI 41–65). High rates of non-relapse mortality (NRM) were observed; 38% (95% CI, 26–50) at 3 years. Although potentially curative, approaches to reduce considerable NRM and chronic GVHD rates are required.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-05-06T21:33:18Z
2024-08-20T12:12:53Z